Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202303159193i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202302033591i

Article Source : PR Newswire
Link : https://www.prnewswire.com/news-releases/qurient-co-ltd-and-tb-alliance-announce-exclusive-license-agreement-for-telacebec-q203-a-new-anti-tuberculosis-agent-301738149.html

Article Source : 바이오스펙테이터
Link : http://www.biospectator.com/view/news_view.php?varAtcId=18181

Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20230202005011/en/Qurient-Announces-Dosing-of-First-Patient-in-Q702-in-Combination-with-KEYTRUDA%C2%AE-in-a-Phase-1b2-Clinical-Study-for-the-Treatment-of-Patients-with-Solid-Tumors

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202301193813i

Article Source : 머니투데이
Link : https://news.mt.co.kr/mtview.php?no=2022120109525454587

Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20221123005365/en/Qurient-Announces-Dosing-of-First-Patient-in-Q901-Phase-12-Clinical-Study-for-the-Treatment-of-Patients-with-Solid-Tumors

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202210316313i

Article Source : 약업신문
Link : https://www.yakup.com/news/index.html?mode=view&cat=12&nid=274957

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202210055579i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202209278442i

큐리언트는 선택적 CDK7 억제제인 Q901과 MSD의 항PD-1 면역항암제 키트루다®(KEYTRUDA® – 성분명: 펨브롤리주맙)의 병용요법에 대한 임상연구를 위해 글로벌 제약회사 MSD(미국 머크)와 공동개발계약을 체결했다고 14일 밝혔다. 본 계약은 MSD의 항PD-1 면역항암제 키트루다®와 큐리언트의 선택적....

● Q901 is a novel highly selective CDK7 inhibitor ● Q901 is ready for dose escalation study in the U.S. for the treatment of selected advanced solid tumors (NCT 05394103) ● The p....